School of Public Health and Community Medicine, UNSW Medicine, Sydney, Australia; National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital Network, Westmead, New South Wales, Australia.
Office of Health Protection, Department of Health, Canberra, Australia.
J Epidemiol Glob Health. 2016 Sep;6(3):197-209. doi: 10.1016/j.jegh.2015.12.004. Epub 2016 Jan 27.
The World Health Organization (WHO) Western Pacific Region (WPR) Guidelines on verification of measles elimination were established in 2012. This article outlines Australia's approach to addressing the guideline's five lines of evidence, which led to formal verification of elimination by the WHO Regional Verification Commission (RVC) in March 2014.
The criteria were addressed using national measles notifications, data from selected laboratories, the national childhood immunization register, and three national serosurveys (1998/1999, 2002, 2007).
Australia met or exceeded all indicator targets with either national or sentinel data. Laboratory and epidemiological surveillance were of high quality, with 85% of cases documented as imported/import-related (target 80%); coverage with the first dose of measles vaccine was close to 94% in 2008-2012 and second dose coverage increased to 91% in 2012 (target >95%). There is ongoing commitment by the Australian Government to increase immunization coverage, and the absence of sustained transmission of any single measles genotype was demonstrated.
This is the first documentation of the successful application of the WPR RVC guidelines. The indicators afford some flexibility but appear to provide appropriate rigor to judge achievement of measles elimination. Our experience could assist other countries seeking to verify their elimination status.
世界卫生组织(WHO)西太平洋区域(WPR)于 2012 年制定了麻疹消除验证指南。本文概述了澳大利亚为满足指南 5 条证据标准而采取的方法,这使得澳大利亚于 2014 年 3 月获得世界卫生组织区域验证委员会(RVC)的正式认证。
使用国家麻疹监测数据、来自选定实验室的数据、国家儿童免疫登记和 3 项全国血清学调查(1998/1999 年、2002 年、2007 年)来满足标准。
澳大利亚使用国家或哨点数据满足或超过了所有指标目标。实验室和流行病学监测质量高,85%的病例被记录为输入/输入相关病例(目标 80%);2008-2012 年麻疹疫苗首剂覆盖率接近 94%,2012 年第二剂覆盖率增加到 91%(目标>95%)。澳大利亚政府承诺继续提高免疫覆盖率,并且证明了任何单一麻疹基因型都没有持续传播。
这是首次成功应用 WPR RVC 指南的证明。这些指标提供了一定的灵活性,但似乎为判断麻疹消除的实现提供了适当的严谨性。我们的经验可以为其他寻求验证其消除状态的国家提供帮助。